Immunovant Quarterly Balance Sheets Chart
Quarterly
|
Annual
Immunovant Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | ||||||||||||||||||||||||
| current assets: | ||||||||||||||||||||||||
| cash and cash equivalents | 598,912,000 | 713,971,000 | 374,685,000 | 472,941,000 | 560,005,000 | 635,365,000 | 690,937,000 | 269,928,000 | 329,960,000 | 376,532,000 | 432,608,000 | 405,773,000 | ||||||||||||
| accounts receivable | 1,936,000 | 2,084,000 | 2,224,000 | 1,876,000 | 2,417,000 | 5,337,000 | 1,029,000 | 1,421,000 | 823,000 | 700,000 | 704,000 | 3,782,000 | 13,177,000 | 12,229,000 | ||||||||||
| prepaid expenses and other current assets | 50,915,000 | 51,180,000 | 35,632,000 | 32,555,000 | 26,625,000 | 24,902,000 | 18,810,000 | 19,828,000 | 19,232,000 | 26,916,000 | 21,110,000 | 16,536,000 | 15,922,000 | 6,253,000 | 13,477,000 | 4,840,000 | 5,821,000 | |||||||
| total current assets | 651,763,000 | 767,662,000 | 412,541,000 | 507,372,000 | 589,047,000 | 665,770,000 | 710,776,000 | 291,177,000 | 350,015,000 | 404,333,000 | 454,422,000 | 426,091,000 | 456,304,000 | 512,931,000 | 540,480,000 | 563,792,000 | 384,826,000 | 409,006,000 | 429,428,000 | 450,266,000 | 286,116,000 | 109,076,000 | 126,570,000 | 1,762,453 |
| property and equipment | 737,000 | 844,000 | 752,000 | 671,000 | 565,000 | 462,000 | 376,000 | 304,000 | 325,000 | 333,000 | 362,000 | 312,000 | 328,000 | 330,000 | 250,000 | 209,000 | 193,000 | 201,000 | 132,000 | 136,000 | 112,000 | 65,000 | 49,000 | |
| other assets | 8,940,000 | 7,618,000 | 7,617,000 | 7,619,000 | ||||||||||||||||||||
| total assets | 661,440,000 | 776,222,000 | 420,932,000 | 515,707,000 | 589,678,000 | 666,365,000 | 711,446,000 | 292,070,000 | 351,222,000 | 405,838,000 | 456,243,000 | 428,146,000 | 458,656,000 | 515,564,000 | 543,182,000 | 566,732,000 | 388,027,000 | 412,489,000 | 433,029,000 | 453,895,000 | 290,291,000 | 109,387,000 | 126,619,000 | 117,787,151 |
| liabilities and stockholders’ equity | ||||||||||||||||||||||||
| current liabilities: | ||||||||||||||||||||||||
| accounts payable | 7,843,000 | 17,656,000 | 19,816,000 | 20,727,000 | 11,035,000 | 7,155,000 | 3,910,000 | 7,511,000 | 26,459,000 | 1,353,000 | 14,004,000 | 7,461,000 | 1,066,000 | 18,629,000 | 3,827,000 | 4,243,000 | 3,107,000 | 2,432,000 | 2,100,000 | 5,787,000 | 8,011,000 | 1,190,000 | 2,812,000 | |
| accrued expenses and other current liabilities | 45,057,000 | |||||||||||||||||||||||
| total current liabilities | 52,900,000 | 68,775,000 | 68,315,000 | 66,653,000 | 45,018,000 | 48,608,000 | 32,102,000 | 40,259,000 | 51,357,000 | 43,297,000 | 41,259,000 | 31,784,000 | 21,244,000 | 44,520,000 | 36,354,000 | 28,383,000 | 20,523,000 | 18,771,000 | 16,485,000 | 12,810,000 | 19,544,000 | 337,625 | ||
| total liabilities | 52,900,000 | 68,775,000 | 68,315,000 | 66,653,000 | 45,018,000 | 48,608,000 | 32,102,000 | 40,259,000 | 51,357,000 | 43,344,000 | 41,565,000 | 32,398,000 | 22,163,000 | 45,739,000 | 38,034,000 | 30,335,000 | 22,495,000 | 21,009,000 | 18,877,000 | 15,489,000 | 22,516,000 | 15,318,000 | 14,757,000 | 4,362,625 |
| commitments and contingencies | ||||||||||||||||||||||||
| stockholders’ equity: | ||||||||||||||||||||||||
| series a preferred stock, par value 0.0001 per share, 10,000 shares authorized, issued and outstanding at june 30, 2025 and march 31, 2025 | ||||||||||||||||||||||||
| preferred stock, par value 0.0001 per share, 10,000,000 shares authorized, no shares issued and outstanding at june 30, 2025 and march 31, 2025 | ||||||||||||||||||||||||
| common stock | 16,000 | 16,000 | 14,000 | 14,000 | 14,000 | 14,000 | 14,000 | 13,000 | 13,000 | 13,000 | 13,000 | 12,000 | 12,000 | 12,000 | 12,000 | 12,000 | 10,000 | 10,000 | 10,000 | 10,000 | 8,000 | 5,000 | 5,000 | 353 |
| additional paid-in capital | 1,966,923,000 | 1,945,495,000 | 1,483,198,000 | 1,469,082,000 | 1,455,659,000 | 1,441,518,000 | 1,430,294,000 | 950,231,000 | 939,554,000 | 927,976,000 | 920,197,000 | 840,661,000 | 832,504,000 | 824,796,000 | 812,933,000 | 802,774,000 | 594,377,000 | 590,425,000 | 584,174,000 | 577,341,000 | 385,691,000 | 185,306,000 | 182,679,000 | 4,692,712 |
| accumulated other comprehensive income | 1,737,000 | 1,459,000 | 2,479,000 | 1,910,000 | 1,820,000 | 1,908,000 | -600,000 | 513,000 | 582,000 | 852,000 | 1,383,000 | -1,237,000 | -263,000 | 404,000 | 419,000 | 442,000 | 273,000 | 467,000 | 10,000 | -16,000 | -147,000 | |||
| accumulated deficit | -1,360,136,000 | -1,239,523,000 | -1,133,074,000 | -1,021,952,000 | -912,833,000 | -825,683,000 | -750,364,000 | -698,946,000 | -640,284,000 | -566,347,000 | -506,915,000 | -443,688,000 | -395,760,000 | -355,387,000 | -308,216,000 | -266,831,000 | -229,128,000 | -198,657,000 | -170,499,000 | -138,723,000 | -117,934,000 | -91,226,000 | -70,675,000 | |
| total stockholders’ equity | 608,540,000 | 707,447,000 | 352,617,000 | 449,054,000 | 544,660,000 | 617,757,000 | 679,344,000 | 251,811,000 | 299,865,000 | 362,494,000 | 414,678,000 | 395,748,000 | 436,493,000 | 469,825,000 | 505,148,000 | 536,397,000 | 365,532,000 | 391,480,000 | 414,152,000 | 438,406,000 | 267,775,000 | 94,069,000 | 111,862,000 | 5,000,006 |
| total liabilities and stockholders’ equity | 661,440,000 | 776,222,000 | 420,932,000 | 515,707,000 | 589,678,000 | 666,365,000 | 711,446,000 | 292,070,000 | 351,222,000 | 405,838,000 | 456,243,000 | 428,146,000 | 458,656,000 | 515,564,000 | 543,182,000 | 566,732,000 | 388,027,000 | 412,489,000 | 433,029,000 | 453,895,000 | 290,291,000 | 109,387,000 | 126,619,000 | 117,787,151 |
| income tax receivable | 427,000 | 166,000 | 185,000 | 632,000 | 548,000 | 481,000 | 40,000 | 24,000 | 36,000 | |||||||||||||||
| operating lease right-of-use assets | 98,000 | 22,000 | 45,000 | 66,000 | 133,000 | 294,000 | 589,000 | 882,000 | 1,172,000 | 1,459,000 | 1,743,000 | 2,024,000 | 2,303,000 | 2,452,000 | 2,731,000 | 3,008,000 | 3,282,000 | 3,469,000 | 3,493,000 | 4,063,000 | ||||
| accrued expenses | 50,748,000 | 48,476,000 | 45,879,000 | 33,914,000 | 41,300,000 | 27,886,000 | 32,134,000 | 23,979,000 | 40,421,000 | 26,050,000 | 23,138,000 | 19,013,000 | 24,575,000 | 31,448,000 | 23,058,000 | 16,331,000 | 15,160,000 | 13,281,000 | 5,787,000 | 10,095,000 | 10,938,000 | 8,705,000 | 306,115 | |
| current portion of operating lease liabilities | 98,000 | 23,000 | 47,000 | 69,000 | 138,000 | 306,000 | 614,000 | 919,000 | 1,173,000 | 1,205,000 | 1,185,000 | 1,165,000 | 1,145,000 | 1,079,000 | 1,082,000 | 1,085,000 | 1,179,000 | 1,104,000 | 1,102,000 | 1,102,000 | ||||
| due to roivant sciences ltd. | 273,000 | 15,000 | 350,000 | 171,000 | 134,000 | 336,000 | 3,190,000 | 3,134,000 | ||||||||||||||||
| series a preferred stock, par value 0.0001 per share, 10,000 shares authorized, issued and outstanding at march 31, 2025 and march 31, 2024 | ||||||||||||||||||||||||
| preferred stock, par value 0.0001 per share, 10,000,000 shares authorized, no shares issued and outstanding at march 31, 2025 and march 31, 2024 | ||||||||||||||||||||||||
| series a preferred stock, par value 0.0001 per share, 10,000 shares authorized, issued and outstanding at december 31, 2024 and march 31, 2024 | ||||||||||||||||||||||||
| preferred stock, par value 0.0001 per share, 10,000,000 shares authorized, no shares issued and outstanding at december 31, 2024 and march 31, 2024 | ||||||||||||||||||||||||
| series a preferred stock, par value 0.0001 per share, 10,000 shares authorized, issued and outstanding at september 30, 2024 and march 31, 2024 | ||||||||||||||||||||||||
| preferred stock, par value 0.0001 per share, 10,000,000 shares authorized, no shares issued and outstanding at september 30, 2024 and march 31, 2024 | ||||||||||||||||||||||||
| series a preferred stock, par value 0.0001 per share, 10,000 shares authorized, issued and outstanding at june 30, 2024 and march 31, 2024 | ||||||||||||||||||||||||
| preferred stock, par value 0.0001 per share, 10,000,000 shares authorized, no shares issued and outstanding at june 30, 2024 and march 31, 2024 | ||||||||||||||||||||||||
| operating lease liabilities, net of current portion | 47,000 | 306,000 | 614,000 | 919,000 | 1,219,000 | 1,972,000 | 2,238,000 | 2,392,000 | 2,679,000 | 2,972,000 | ||||||||||||||
| series a preferred stock, par value 0.0001 per share, 10,000 shares authorized, issued and outstanding at march 31, 2024 and march 31, 2023 | ||||||||||||||||||||||||
| preferred stock, par value 0.0001 per share, 10,000,000 shares authorized, no shares issued and outstanding at march 31, 2024 and march 31, 2023 | ||||||||||||||||||||||||
| series a preferred stock, par value 0.0001 per share, 10,000 shares authorized, issued and outstanding at december 31, 2023 and march 31, 2023 | ||||||||||||||||||||||||
| preferred stock, par value 0.0001 per share, 10,000,000 shares authorized, no shares issued and outstanding at december 31, 2023 and march 31, 2023 | ||||||||||||||||||||||||
| series a preferred stock, par value 0.0001 per share, 10,000 shares authorized, issued and outstanding at september 30, 2023 and march 31, 2023 | ||||||||||||||||||||||||
| preferred stock, par value 0.0001 per share, 10,000,000 shares authorized, no shares issued and outstanding at september 30, 2023 and march 31, 2023 | ||||||||||||||||||||||||
| series a preferred stock, par value 0.0001 per share, 10,000 shares authorized, issued and outstanding at june 30, 2023 and march 31, 2023 | ||||||||||||||||||||||||
| preferred stock, par value 0.0001 per share, 10,000,000 shares authorized, no shares issued and outstanding at june 30, 2023 and march 31, 2023 | ||||||||||||||||||||||||
| series a preferred stock, par value 0.0001 per share, 10,000 shares authorized, issued and outstanding at march 31, 2023 and march 31, 2022 | ||||||||||||||||||||||||
| preferred stock, par value 0.0001 per share, 10,000,000 shares authorized, no shares issued and outstanding at march 31, 2023 and march 31, 2022 | ||||||||||||||||||||||||
| series a preferred stock, par value 0.0001 per share, 10,000 shares authorized, issued and outstanding at december 31, 2022 and march 31, 2022 | ||||||||||||||||||||||||
| preferred stock, par value 0.0001 per share, 10,000,000 shares authorized, no shares issued and outstanding at december 31, 2022 and march 31, 2022 | ||||||||||||||||||||||||
| series a preferred stock, par value 0.0001 per share, 10,000 shares authorized, issued and outstanding at september 30, 2022 and march 31, 2022 | ||||||||||||||||||||||||
| preferred stock, par value 0.0001 per share, 10,000,000 shares authorized, no shares issued and outstanding at september 30, 2022 and march 31, 2022 | ||||||||||||||||||||||||
| cash | 427,205,000 | 493,817,000 | 527,003,000 | 558,952,000 | 379,005,000 | 400,146,000 | 421,974,000 | 444,372,000 | 280,279,000 | 100,571,000 | 123,530,000 | 1,610,350 | ||||||||||||
| series a preferred stock, par value 0.0001 per share, 10,000 shares authorized, issued and outstanding at june 30, 2022 and march 31, 2022 | ||||||||||||||||||||||||
| preferred stock, par value 0.0001 per share, 10,000,000 shares authorized, no shares issued and outstanding at june 30, 2022 and march 31, 2022 | ||||||||||||||||||||||||
| series a preferred stock, par value 0.0001 per share, 10,000 shares authorized, issued and outstanding at march 31, 2022 and march 31, 2021 | ||||||||||||||||||||||||
| preferred stock, par value 0.0001 per share, 10,000,000 shares authorized, no shares issued and outstanding at march 31, 2022 and march 31, 2021 | ||||||||||||||||||||||||
| operating lease liabilities, net of current portion, and other noncurrent liabilities | 1,680,000 | 1,952,000 | ||||||||||||||||||||||
| series a preferred stock, par value 0.0001 per share, 10,000 shares authorized, issued and outstanding at december 31, 2021 and march 31, 2021 | ||||||||||||||||||||||||
| preferred stock, par value 0.0001 per share, 10,000,000 shares authorized, no shares issued and outstanding at december 31, 2021 and march 31, 2021 | ||||||||||||||||||||||||
| series a preferred stock, par value 0.0001 per share, 10,000 shares authorized, issued and outstanding at september 30, 2021 and march 31, 2021 | ||||||||||||||||||||||||
| preferred stock, par value 0.0001 per share, 10,000,000 shares authorized, no shares issued and outstanding at september 30, 2021 and march 31, 2021 | ||||||||||||||||||||||||
| series a preferred stock, par value 0.0001 per share, 10,000 shares authorized, issued and outstanding at june 30, 2021 and march 31, 2021 | ||||||||||||||||||||||||
| preferred stock, par value 0.0001 per share, 10,000,000 shares authorized, no shares issued and outstanding at june 30, 2021 and march 31, 2021 | ||||||||||||||||||||||||
| prepaid expenses | 8,312,000 | 6,973,000 | 5,854,000 | 5,813,000 | 5,460,000 | 44,000 | 152,103 | |||||||||||||||||
| value-added tax receivable | 3,009,000 | 2,996,000 | ||||||||||||||||||||||
| deferred offering costs | 246,000 | |||||||||||||||||||||||
| series a preferred stock, par value 0.0001 per share, 10,000 shares authorized, issued and outstanding at march 31, 2021 and march 31, 2020 | ||||||||||||||||||||||||
| preferred stock, par value 0.0001 per share, 10,000,000 shares authorized, no shares issued and outstanding at march 31, 2021 and march 31, 2020 | ||||||||||||||||||||||||
| accumulated other comprehensive loss | -298,000 | -222,000 | ||||||||||||||||||||||
| series a preferred stock, par value 0.0001 per share, 10,000 shares authorized, issued and outstanding at december 31, 2020 and march 31, 2020 | ||||||||||||||||||||||||
| preferred stock, par value 0.0001 per share, 10,000,000 shares authorized, no shares issued and outstanding at december 31, 2020 and march 31, 2020 | ||||||||||||||||||||||||
| series a preferred stock, par value 0.0001 per share, 10,000 shares authorized, issued and outstanding at september 30, 2020 and march 31, 2020 | ||||||||||||||||||||||||
| preferred stock, par value 0.0001 per share, 10,000,000 shares authorized, no shares issued and outstanding at september 30, 2020 and march 31, 2020 | ||||||||||||||||||||||||
| series a preferred stock, par value 0.0001 per share, 10,000 shares authorized, issued and outstanding at june 30, 2020 and march 31, 2020 | ||||||||||||||||||||||||
| preferred stock, par value 0.0001 per share, 10,000,000 shares authorized, no shares issued and outstanding at june 30, 2020 and march 31, 2020 | ||||||||||||||||||||||||
| series a preferred stock, par value 0.0001 per share, 10,000 shares authorized, issued and outstanding at march 31, 2020 and no shares authorized at march 31, 2019 | ||||||||||||||||||||||||
| preferred stock, par value 0.0001 per share, 10,000,000 shares authorized, no shares issued and outstanding at march 31, 2020 and no shares authorized at march 31, 2019 | ||||||||||||||||||||||||
| common stock subscribed | ||||||||||||||||||||||||
| income tax payable | 106,000 | |||||||||||||||||||||||
| stockholders’ equity:* | ||||||||||||||||||||||||
| series a preferred stock, par value 0.0001 per share, 10,000 shares authorized, issued and outstanding at december 31, 2019 and no shares authorized at march 31, 2019 | ||||||||||||||||||||||||
| preferred stock, par value 0.0001 per share, 10,000,000 shares authorized, no shares issued and outstanding at december 31, 2019 and no shares authorized at march 31, 2019 | ||||||||||||||||||||||||
| current assets | ||||||||||||||||||||||||
| cash and marketable securities held in trust account | 116,024,698 | |||||||||||||||||||||||
| current liabilities | ||||||||||||||||||||||||
| accrued offering costs | ||||||||||||||||||||||||
| income taxes payable | 31,510 | |||||||||||||||||||||||
| promissory note – related party | ||||||||||||||||||||||||
| deferred underwriting fee payable | 4,025,000 | |||||||||||||||||||||||
| common stock subject to possible redemption, 10,842,452 shares at redemption value | 108,424,520 | |||||||||||||||||||||||
| stockholders’ equity | ||||||||||||||||||||||||
| retained earnings/ | 306,941 |
We provide you with 20 years of balance sheets for Immunovant stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Immunovant. Explore the full financial landscape of Immunovant stock with our expertly curated balance sheets.
The information provided in this report about Immunovant stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.